suggested that some forms of obesity may be characterized by a selective leptin resistance, limited to its favorable metabolic effects (satiety and weight loss), while its sympathoexcitatory effects on the cardiovascular system are maintained (Correia et al., 2002
It helps increase insulin production, reduce the secretion of glucagon (a hormone that raises blood sugar), and slows down the emptying of your stomach
In rats, GCLC has a Km for glutamate that is about 10-fold higher, which is higher than the cellular glutamate concentration in most tissues
For FDA-approved GLP-1 receptor agonists, the safety profile is well-characterized through extensive clinical trial data and post-marketing surveillance
The MHRA has issued a Drug Safety Update highlighting this risk, and testing should be considered if you are symptomatic